Ten hot line sessions have been announced for ESC Congress 2025.

The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid. Access the full programme here.

Hot Line 1

Friday 29th August, 11:00am – 12:00pm (CEST)

• POTCAST – a Randomized Controlled Trial of Arrhythmia prevention using targeted plasma potassium levels in ICD Patients – Presented by Christian Jons
• AMALFI: Active Monitoring for Atrial Fibrillation – Presented by Louise Bowman
• DIGIT-HF: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction – Presented by Udo Bavendiek
• DOUBLE-CHOICE: Anesthesia strategies and self-expanding valve types for TAVI – Presented by Mohamed Abdel-Wahab

Hot Line 2

Saturday 30th August, 08:15am – 09:45am (CEST)

• DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure – Presented by David Berg
• VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure – Presented by Faiez Zannad
• VICTORIA: Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction – Presented by Javed Butler
• ODYSSEY-HCM: Mavacamten in nHCM – Presented by Milind Desai
• MAPLE-HCM: aficamten vs metoprolol in oHCM – Presented by Pablo Garcia-Pavia

Hot Line 3

Saturday 30th August, 11:00am – 12:00pm (CEST)

• REBOOT-CNIC: betablockers after infarction with LVEF greater than 40% – Presented by Borja Ibanez
• THE BETAMI-DANBLOCK TRIAL: RANDOMIZED DISCONTINUATION OF BETA-BLOCKERS AFTER MYOCARDIAL INFARCTION – Presented by Dan Atar
• REBOOT/BETAMI/DANBLOCK/CAPITAL-RCT: Beta-Blockers after MI with Mildly Reduced EF (an IPD meta-analysis) – Presented by Francisco Javier Rossello
• REFINE ICD: Efficacy of ICD therapy in higher risk post-MI patients with better-preserved LV function – Presented by Derek Exner

Hot Line 4

Saturday 30th August, 16:15pm – 17:15pm (CEST)

• BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension – Presented by Bryan Williams
• KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk – Presented by Neha Pagidipati
• Essence-TIMI 73b – Presented by Brian Bergmark
• VICTORION-Difference study: Inclisiran-based strategy vs standard of care – Presented by Ulf Landmesser

Hot Line 5

Saturday 30th August, 17:30pm – 18:30pm (CEST)

• DANCAVAS 2: Screening and intervention to prevent cardiovascular disease and death – Presented by Axel Cosmus Pyndt Dierderichsen
• PREVENT-MINS trial:Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery – Presented by Wojciech Szczeklik
• ABC-AF study - a randomised controlled study of personalised treatment to reduce stroke or death in atrial fibrillation – Presented by Jonas Oldgren
• HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism – Presented by Gregory Piazza

Hot Line 6

Sunday 31st August, 08:15am – 09:45am (CEST)

• SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease
• The PULSE randomized controlled trial – Presented by Ovidio De Filippo
• The AQUATIC trial – Presented by Martine Gilard
• The DUAL-ACS Trial: Duration of DAPT in ACS – Presented by David Newby
• OPTION-STEMI: Timing of complete revascularization during index hospitalization in patients with STEMI and multivessel disease – Presented by Youngkeun Ahn

Hot Line 7

Sunday 31st August, 16:15pm – 17:15pm (CEST)

• NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome – Presented by Pedro Lemos
• TAILORED-CHIP: Tailored Antiplatelet Therapy for Complex High-Risk PCI – Presented by Duk-Woo Park
• TARGET-FIRST: Early aspirin discontinuation after PCI in acute MI patients – Presented by Giuseppe Tarantin
• DAPT-SHOCK-AMI trial, Cangrelor in cardiogenic shock – Presented by Zuzana Motovska

Hot Line 8

Sunday 31st August, 17:30pm – 18:30pm (CEST)

• ALONE-AF: Discontinuing long-Term oral anticoagulation after successful atrial fibrillation ablation – Presented by Boyoung Joung
• BEAT PAROX AF: a randomized comparison of PFA vs RFA – Presented by Pierre Jais
• CUVIA-PRR: Digital twin-guided rotor ablation for persistent atrial fibrillation – Presented by Renato Lopes

Hot Line 9

Monday 1st September, 08:15am – 09:45am (CEST)

• PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy – Presented by Renato Lopes
• HELP-MI SWEDEHEART – Randomised H. pylori screening after MI – Presented by Robin Hofmann
• Project MHYH: One-Year Results – Presented by Thomas Crawford
• IMPACT-BP Implementation of a Combination Intervention for Sustainable Blood Pressure Control in rural South Africa – Presented by Thomas Andrew Gaziano

Hot Line 10

Monday 1st September, 13:45pm – 15:00pm (CEST)

• NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency – Presented by Subodh Verma
• TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome – Presented by Anders Jeppsson
• The TOP-CABG trial – Presented by Xin Yuan
• OPINION Trial: 1-Year Outcomes – Presented by Yang Wang

References

ESC 365. Programme. 2025. https://esc365.escardio.org/esc-congress/programme?text=&docType=All&days=2025-08-29&session_type=Hot%20Line&page=1&vue=cards (accessed 09 July 2025).